Table 3.
Predictors of TNF inhibitors included in the meta-analysis
| Risk factor (number of studies) | Effect size (95% CI) | P value | I2 | I2heterogeneity | Egger’s test |
|---|---|---|---|---|---|
| Sociodemographic-related risk factors | |||||
| Age > = 50 (7) | OR 0.98 (0.97, 0.99) | < 0.00001 | 17% | 0.3 | 0.01 |
| Female gender (8) | OR 0.61 (0.50, 0.75) | < 0.00001 | 63% | 0.008 | NR |
| Current of ex-smoker (7) | OR 0.86 (0.75, 0.99) | 0.04 | 67% | 0.006 | NR |
| Disease-related risk factors | |||||
| RF positive (6) | OR 0.99 (0.98, 1.00) | 0.13 | 11% | 0.34 | NR |
| Treatment-related risk factors | |||||
| Prior or concurrent use of MTX (6) | OR 1.18 (0.87, 1.6) | 0.29 | 77% | < 0.0005 | NR |
| Prior or concurrent use of steroids (4) | OR 1.03 (0.86, 1.24) | 0.71 | 69% | 0.02 | NR |